Thibault Houles

Dr. Thibault Houles

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2023 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
THThibault Houles
Thibault Houles
JBJonathan Boucher
Jonathan Boucher
GLGeneviève Lavoie
Geneviève Lavoie
GMGraham MacLeod
Graham MacLeod
SLSichun Lin
Sichun Lin
PRPhilippe P. Roux
Philippe P. Roux
CDK12 is a transcriptional cyclin-dependent kinase (CDK) that interacts with cyclin K to regulate different aspects of gene expression. The CDK12-cyclin K complex phosphorylates several substrates, including RNA polymerase II (Pol II), and thereby regulates transcription elongation, RNA splicing, as well as cleavage and polyadenylation. Because of its implication in cancer, including breast cancer and melanoma, multiple pharmacological inhibitors of CDK12 have been identified to date, including THZ531 and SR-4835. While both CDK12 inhibitors affect Poll II phosphorylation, we found that SR-4835 uniquely promotes cyclin K degradation via the proteasome. Using loss-of-function genetic screening, we found that SR-4835 cytotoxicity depends on a functional CUL4-RBX1-DDB1 ubiquitin ligase complex. Consistent with this, we show that DDB1 is required for cyclin K degradation, and that SR-4835 promotes DDB1 interaction with the CDK12-cyclin K complex. Docking studies and structure-activity relationship analyses of SR-4835 revealed the importance of the benzimidazole side-chain in molecular glue activity. Together, our results indicate that SR-4835 acts as a molecular glue that recruits the CDK12-cyclin K complex to the CUL4-RBX1-DDB1 ubiquitin ligase complex to target cyclin K for degradation.

29 October 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
THThibault Houles
Thibault Houles
GLGeneviève Lavoie
Geneviève Lavoie
SNSami Nourreddine
Sami Nourreddine
WCWinnie Cheung
Winnie Cheung
ÉVÉric Vaillancourt-Jean
Éric Vaillancourt-Jean
PRPhilippe P. Roux
Philippe P. Roux
Melanoma is the deadliest form of skin cancer and considered intrinsically resistant to chemotherapy. Nearly all melanomas harbor mutations that activate the RAS/mitogen-activated protein kinase (MAPK) pathway, which contributes to drug resistance via poorly described mechanisms. Herein we show that the RAS/MAPK pathway regulates the activity of cyclin-dependent kinase 12 (CDK12), which is a transcriptional CDK required for genomic stability. We find that melanoma cells harbor constitutively high CDK12 activity, and that its inhibition decreases the expression of long genes containing multiple exons, including many genes involved in DNA repair. Conversely, our results show that CDK12 inhibition promotes the expression of short genes with few exons, including many growth-promoting genes regulated by the AP-1 and NF-κB transcription factors. Inhibition of these pathways strongly synergize with CDK12 inhibitors to suppress melanoma growth, suggesting promising drug combinations for more effective melanoma treatment.

14 June 2021 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
ECEmilie L. Cerezo
Emilie L. Cerezo
THThibault Houles
Thibault Houles
OLOriane Lié
Oriane Lié
MSMarie-Kerguelen Sarthou
Marie-Kerguelen Sarthou
CACharlotte Audoynaud
Charlotte Audoynaud
YRYves Romeo
Yves Romeo
Ribosome biogenesis lies at the nexus of various signaling pathways coordinating protein synthesis with cell growth and proliferation. This process is regulated by well-described transcriptional mechanisms, but a growing body of evidence indicates that other levels of regulation exist. Here we show that the Ras/mitogen-activated protein kinase (MAPK) pathway stimulates post-transcriptional stages of human ribosome synthesis. We identify RIOK2, a pre-40S particle assembly factor, as a new target of the MAPK-activated kinase RSK. RIOK2 phosphorylation by RSK stimulates cytoplasmic maturation of late pre-40S particles, which is required for optimal protein synthesis and cell proliferation. RIOK2 phosphorylation facilitates its release from pre-40S particles and its nuclear re-import, prior to completion of small ribosomal subunits. Our results bring a detailed mechanistic link between the Ras/MAPK pathway and the maturation of human pre-40S particles, which opens a hitherto poorly explored area of ribosome biogenesis.

11 September 2024 in Trends in Biochemical Sciences
Verified
Journal Article
Closed access
THThibault Houles
Thibault Houles
SYSang-Oh Yoon
Sang-Oh Yoon
PRPhilippe P. Roux
Philippe P. Roux

Verified
Journal Article
Open access
PDF file
KBKalil Batnini
Kalil Batnini
THThibault Houles
Thibault Houles
OKOlivier Kirsh
Olivier Kirsh
SMStanislas Du Manoir
Stanislas Du Manoir
MZMehdi Zaroual
Mehdi Zaroual
GRGenevieve Rodier
Genevieve Rodier
E4F1 is essential for early embryonic mouse development and for controlling the balance between proliferation and survival of actively dividing cells. We previously reported that E4F1 is essential for the survival of murine p53-deficient cancer cells by controlling the expression of genes involved in mitochondria functions and metabolism, and in cell-cycle checkpoints, including CHEK1, a major component of the DNA damage and replication stress responses. Here, combining ChIP-Seq and RNA-Seq approaches, we identified the transcriptional program directly controlled by E4F1 in Human Triple-Negative Breast Cancer cells (TNBC). E4F1 binds and regulates a limited list of direct target genes (57 genes) in these cells, including the human CHEK1 gene and, surprisingly, also two other genes encoding post-transcriptional regulators of the ATM/ATR-CHK1 axis, namely, the TTT complex component TTI2 and the phosphatase PPP5C, that are essential for the folding and stability, and the signaling of ATM/ATR kinases, respectively. Importantly, E4F1 also binds the promoter of these genes in vivo in Primary Derived Xenograft (PDX) of human TNBC. Consequently, the protein levels and signaling of CHK1 but also of ATM/ATR kinases are strongly downregulated in E4F1-depleted TNBC cells resulting in a deficiency of the DNA damage and replicative stress response in these cells. The E4F1-depleted cells fail to arrest into S-phase upon treatment with the replication-stalling agent Gemcitabine, and are highly sensitized to this drug, as well as to other DNA-damaging agents, such as Cisplatin. Altogether, our data indicate that in breast cancer cells the ATM/ATR-CHK1 signaling pathway and DNA damage-stress response are tightly controlled at the transcriptional and post-transcriptional level by E4F1.

19 February 2026 in Oncogene
Verified
Journal Article
Closed access
PDF file
MAMariana Acevedo
Mariana Acevedo
FDFlorence Dô
Florence Dô
FEFiras El-Mortada
Firas El-Mortada
PTPierre-Luc Tanguay
Pierre-Luc Tanguay
LVLaure Voisin
Laure Voisin
MSMarc Servant
Marc Servant